Efficacy of an Oncolytic Adenovirus Driven by a Chimeric Promoter and Armed with Decorin Against Renal Cell Carcinoma
Author:
Affiliation:
1. Cancer Institute, Xuzhou Medical University, Xuzhou, China; and
2. Center of Clinical Oncology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Publisher
Mary Ann Liebert Inc
Subject
Genetics,Molecular Biology,Molecular Medicine
Link
https://www.liebertpub.com/doi/pdf/10.1089/hum.2019.352
Reference36 articles.
1. Current Status and Future Directions of Immunotherapy in Renal Cell Carcinoma
2. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
3. Oncolytic adenovirus: A tool for cancer therapy in combination with other therapeutic approaches
4. An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells
Cited by 22 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Spatial computational modelling illuminates the role of the tumour microenvironment for treating glioblastoma with immunotherapies;npj Systems Biology and Applications;2024-08-18
2. Multiple aspects of matrix stiffness in cancer progression;Frontiers in Oncology;2024-07-02
3. TGF-β signaling in health, disease and therapeutics;Signal Transduction and Targeted Therapy;2024-03-22
4. Construction and application of adenoviral vectors;Molecular Therapy - Nucleic Acids;2023-12
5. Ki67-targeted oncolytic adenovirus expressing IL-15 improves intratumoral T cell infiltration and PD-L1 expression in glioblastoma;Virology;2023-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3